Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese  Click to Translate to Myanmar (Burmese)

PANDEMIC ALERT LEVEL
123456
Forum Home Forum Home > Main Forums > Latest News
  New Posts New Posts RSS Feed - Remdesivir Doesn't Help
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic since 2005; Coronavirus COVID-19 Pandemic Discussion Forum.

Remdesivir Doesn't Help

 Post Reply Post Reply
Author
Message
ViQueen24 View Drop Down
Adviser Group
Adviser Group
Avatar

Joined: May 14 2013
Location: Verona, PA
Status: Online
Points: 7375
Post Options Post Options   Thanks (0) Thanks(0)   Quote ViQueen24 Quote  Post ReplyReply Direct Link To This Post Topic: Remdesivir Doesn't Help
    Posted: October 15 2020 at 7:35pm


https://www.msn.com/en-us/health/medical/big-global-study-finds-remdesivir-doesn-t-help-covid-19-patients/ar-BB1a4MeV?ocid=AMZN

CNN

Big global study finds remdesivir doesn't help Covid-19 patients

By John Bonifield  1 hr ago

Feinstein's hug of Graham sparks outrage on the left

Republicans widen counterattack on Facebook and Twitter

CNN logoBig global study finds remdesivir doesn't help Covid-19 patients

In a study it described as both conclusive and disappointing, the World Health Organization said the antiviral drug remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help patients recover any faster, either.


A pharmacist at AMZ Hospital in Dhaka, Bangladesh, with a generic version of remdesivi© Courtesy Dr. Ahmedul Kabir A pharmacist at AMZ Hospital in Dhaka, Bangladesh, with a generic version of remdesivi

Until now, remdesivir has been the only drug that appeared to have specific effects for coronavirus. It was the only drug with an Emergency Use Authorization for Covid-19 from the US Food and Drug Administration.



Results of the WHO study have not been published in a peer-reviewed medical journal. But WHO posted them to a pre-print server.


The WHO study reviewed remdesivir and three other repurposed drugs: hydroxychloroquine, the HIV combination of lopinavir and ritonavir and interferon. None of them helped patients live any longer or get out of the hospital any sooner, WHO said.


The trial was able to generate conclusive evidence on the impact the drugs had on mortality, the need for ventilation, and duration of hospital stay.


"For each drug in the study, the effect on mortality was disappointingly unpromising," WHO said in a statement.


Several other studies had found that hydroxychloroquine, an anti-malarial drug, was of no benefit to coronavirus patients, as had several studies looking at the HIV drug combination.


The study covered more than 11,000 coronavirus patients in 30 countries. "The protocol was designed to involve hundreds of potentially over-stressed hospitals in dozens of countries," the international team of researchers wrote. They said they have submitted their findings to a medical journal.


Prior to the WHO study, a large controlled study of remdesivir in the US found that it shortens recovery time by about a third in severely ill, hospitalized adults with Covid-19, but does little to help those with milder cases.


Gilead Sciences, the drug's maker, said the findings did not mean the drug, sold under the brand name Veklury, is of no benefit.


"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir). We are concerned that the data from this open- label global trial have not undergone the rigorous review required to allow for constructive scientific discussion," Gilead said in a statement.


"The benefits of Veklury have been demonstrated in three randomized, controlled clinical trials, including a randomized, double-blind, placebo-controlled clinical trial -- the gold standard for evaluating the efficacy and safety of investigational drugs."


The WHO-led researchers say their trial, called the Solidarity trial, will continue. "Newer antiviral drugs, immunomodulators and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation via the Solidarity Therapeutics trial," WHO said.


Monoclonal antibody treatments include Regeneron's dual antibody cocktail and Eli Lilly and Co's double antibody therapy.

Back to Top
Dutch Josh View Drop Down
V.I.P. Member
V.I.P. Member


Joined: May 01 2013
Location: Arnhem-Netherla
Status: Offline
Points: 47067
Post Options Post Options   Thanks (0) Thanks(0)   Quote Dutch Josh Quote  Post ReplyReply Direct Link To This Post Posted: October 16 2020 at 12:36am

Maybe it is time to nationalize big pharma so profit does not stay a leading principle in medication...I believe zinc, viamins can make a lot of difference in prevention. The earlier the treatment the better....you should not make profit out of a pandemic !

We cannot solve our problems with the same thinking we used when we created them.
~Albert Einstein
Back to Top
EdwinSm, View Drop Down
Adviser Group
Adviser Group


Joined: April 03 2013
Status: Offline
Points: 18775
Post Options Post Options   Thanks (1) Thanks(1)   Quote EdwinSm, Quote  Post ReplyReply Direct Link To This Post Posted: October 16 2020 at 3:43am

Link to full report:  https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.full.pdf


What is interesting is that this was a study in "real life" hospital situations rather than in a controlled setting (that allowed the pharm company's own test to show it worked).  


Maybe it will still be of benefit in say teaching hospitals in the rich countries if they are not overwhelmed but other cases.  

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down